Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2022-03-22
DOI
10.1080/14740338.2022.2054987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
- (2021) Daisuke Yabe et al. BMJ Open
- Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty ( EMPRISE ) study
- (2021) Elisabetta Patorno et al. DIABETES OBESITY & METABOLISM
- The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
- (2021) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2020) Ona Kinduryte Schorling et al. ADVANCES IN THERAPY
- Japanese Clinical Practice Guideline for Diabetes 2019
- (2020) Eiichi Araki et al. Journal of Diabetes Investigation
- Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
- (2020) Darren K McGuire et al. Lancet Diabetes & Endocrinology
- Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
- (2020) Bettina J. Kraus et al. KIDNEY INTERNATIONAL
- Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
- (2019) Yasuo Terauchi et al. Diabetes Therapy
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
- (2019) Rimei Nishimura et al. ADVANCES IN THERAPY
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
- (2019) Kohei Kaku et al. Expert Opinion On Drug Safety
- Recommendations on the Proper Use of SGLT2 Inhibitors
- (2019) Journal of Diabetes Investigation
- Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
- (2019) Hirohito Sone et al. DIABETES OBESITY & METABOLISM
- Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
- (2018) Ryuzo Kawamori et al. DIABETES OBESITY & METABOLISM
- Incidence of diabetic foot ulcer in Japanese patients with type 2 diabetes mellitus: The Fukuoka diabetes registry
- (2018) Masanori Iwase et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin: A Review in Type 2 Diabetes
- (2018) James E. Frampton DRUGS
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
- (2018) Daisuke Yabe et al. Journal of Diabetes Investigation
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
- (2018) Mojca Lunder et al. Cardiovascular Diabetology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
- (2015) Takashi Kadowaki et al. ADVANCES IN THERAPY
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
- (2015) E. Araki et al. DIABETES OBESITY & METABOLISM
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
- (2013) Ronald C.W. Ma et al. Annals of the New York Academy of Sciences
- Evaluation of Factors Influencing the Natural History of Nocturia in Elderly Subjects: Results of the Fujiwara-kyo Study
- (2012) Akihide Hirayama et al. JOURNAL OF UROLOGY
- Metabolic Syndrome Is a Risk Factor for Acute Cerebral Infarction in a Younger Elderly Kurashiki Population
- (2010) Yasuyuki Ohta et al. Journal of Stroke & Cerebrovascular Diseases
- Revised Equations for Estimated GFR From Serum Creatinine in Japan
- (2009) Seiichi Matsuo et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Prevalence of chronic kidney disease in the Japanese general population
- (2009) Enyu Imai et al. Clinical and Experimental Nephrology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More